DIAMOND — IN VIVO DIAGNOSTIC TECHNOLOGIES (Q2031371): Difference between revisions

From EU Knowledge Graph
Jump to navigation Jump to search
(‎Created claim: summary (P836): THE INTENDED OUTCOME IS THE DESIGN OF TWO ARALTS’ PLANT ACTIVITIES THAT CAN PRODUCE INNOVATIVE TECHNOLOGIES, INCLUDING ADVANCED MANUFACTURING TECHNOLOGIES (AMS), WHICH ARE ESSENTIAL COMPONENTS OF IMAGING EQUIPMENT FOR INNOVATIVE THERAPIES AND AUXILIARY THERAPIES. THE MOLECULES CHOSEN ARE ALL OF SPECIFIC INTEREST OF MAJOR COMPANIES HAVING THEIR REGISTERED OFFICE IN FRIULI-VENEZIA GIULIA (BRACCO IMAGING SPA AND SIGEA SRL), WHICH CURRENTLY SUPPLI...)
(‎Changed an Item)
Property / programme
 
Property / programme: Friuli-Venezia Giulia - ERDF / rank
 
Normal rank

Revision as of 05:23, 24 March 2020

Project in Italy financed by DG Regio
Language Label Description Also known as
English
DIAMOND — IN VIVO DIAGNOSTIC TECHNOLOGIES
Project in Italy financed by DG Regio

    Statements

    0 references
    74,637.09 Euro
    0 references
    149,274.17 Euro
    0 references
    50.0 percent
    0 references
    22 July 2016
    0 references
    29 March 2018
    0 references
    31 March 2018
    0 references
    SERICHIM SRL
    0 references
    0 references

    46°3'23.36"N, 13°15'9.04"E
    0 references
    IL RISULTATO PERSEGUITO CONSISTE NELLA PROGETTAZIONE DI DUE REALTà IMPIANTISTICHE IN GRADO DI PRODURRE CON TECNOLOGIE INNOVATIVE, INCLUSE LE TECNOLOGIE DI PRODUZIONE AVANZATA (AMS), ALCUNI COMPONENTI FONDAMENTALI DI MEZZI DI CONTRASTO PER LA DIAGNOSTICA PER IMMAGINI E DI AUSILIARI PER TERAPIE INNOVATIVE. LE MOLECOLE SCELTE SONO TUTTE DI INTERESSE SPECIFICO DI IMPORTANTI AZIENDE CON SEDE OPERATIVA IN FVG (BRACCO IMAGING SPA E SIGEA SRL), CHE ATTUALMENTE SE NE APPROVVIGIONANO SU MERCATI ESTERI (Italian)
    0 references
    THE INTENDED OUTCOME IS THE DESIGN OF TWO ARALTS’ PLANT ACTIVITIES THAT CAN PRODUCE INNOVATIVE TECHNOLOGIES, INCLUDING ADVANCED MANUFACTURING TECHNOLOGIES (AMS), WHICH ARE ESSENTIAL COMPONENTS OF IMAGING EQUIPMENT FOR INNOVATIVE THERAPIES AND AUXILIARY THERAPIES. THE MOLECULES CHOSEN ARE ALL OF SPECIFIC INTEREST OF MAJOR COMPANIES HAVING THEIR REGISTERED OFFICE IN FRIULI-VENEZIA GIULIA (BRACCO IMAGING SPA AND SIGEA SRL), WHICH CURRENTLY SUPPLIES THEIR SUPPLIES ON FOREIGN MARKETS (English)
    0 references

    Identifiers

    D58I17000050004
    0 references